Abstract: An interchangeable ring system is provided. The interchangeable ring system includes a shank and a head. The shank includes a receiving hole, and the head includes a peg. The peg is removably inserted into the receiving hole such that the head is secured on the shank. The shank includes a clamp at least partially extending into the receiving hole.

Abstract: Delivery devices for a stented prosthetic heart valve. The delivery device includes a spindle, at least one cord, and a covering feature associated with the spindle for selectively covering at least a portion of a stented prosthetic heart valve tethered to the spindle in a delivery state. In some embodiments, the covering feature includes a tip mounted to the spindle. The tip can include an overhang region for selectively covering a portion of the stented prosthetic heart valve. In other embodiments, the tip can include a tip body and a compressible foam bumper. In yet other embodiments, the covering feature includes an outer sheath arranged to selectively cover the stented prosthetic heart valve. The outer sheath can be elastic and stretchable for recapturing a partially expanded prosthesis, for example by including one or more windows covered by a stretchable covering layer.

Abstract: Improved strap type exercising devices comprising an attaching band having an attaching member for attachment to a door knob or the like and two D rings supported by the band together with a pair of straps each extending slidably through a respective one of said D rings and having handles formed at each end of said straps with ankle straps attached to each of said straps adjacent one end thereof, said straps being movable individually or in unison, as desired.

Abstract: The invention provides a method of treating neoplastic disease in a subject, said method comprising the simultaneous, sequential or separate, administration to said subject of an effective amount of (i) an inhibitor of a first EGF, e.g. HB-EGF and (ii) an inhibitor of a second EGF, e.g. AREG. Also described are novel synergistic combinations of EGF inhibitors with topoisomerase inhibitors which attenuate tumour cell growth. Further described are novel anti AREG antibodies.